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IN
IC
ALBACKGROUND & AIMS: No adjuvant therapy has been shown
to extend the survival of patients with hepatocellular carcinoma
(HCC) receiving curative treatment. We investigated whether
injections of activated cytokine-induced killer (CIK) cells
(CD3þ/CD56þ and CD3þ/CD56- T cells and CD3-/CD56þ
natural killer cells) prolongs recurrence-free survival of
patients after curative therapy for HCC. METHODS: We per-
formed a multicenter, randomized, open-label, phase 3 trial of
the efﬁcacy and safety of adjuvant immunotherapy with
activated CIK cells (created by incubation of patients’ pe-
ripheral blood mononuclear cells with interleukin 2 and an
antibody against CD3). The study included 230 patients with
HCC treated by surgical resection, radiofrequency ablation, or
percutaneous ethanol injection at university-afﬁliated hospi-
tals in Korea. Patients were assigned randomly to receive
immunotherapy (injection of 6.4  109 autologous CIK cells,
16 times during 60 weeks) or no adjuvant therapy (controls).
The primary end point was recurrence-free survival; sec-
ondary end points included overall survival, cancer-speciﬁc
survival, and safety. RESULTS: The median time of
recurrence-free survival was 44.0 months in the immuno-
therapy group and 30.0 months in the control group (hazard
ratio with immunotherapy, 0.63; 95% conﬁdence interval
[CI], 0.43–0.94; P ¼ .010 by 1-sided log-rank test). Hazard
ratios also were lower in the immunotherapy than in the
control group for all-cause death (0.21; 95% CI, 0.06–0.75;
P ¼ .008) and cancer-related death (0.19; 95% CI, 0.04–0.87;
P ¼ .02). A signiﬁcantly higher proportion of patients in the
immunotherapy group than in the control group had an
adverse event (62% vs 41%; P ¼ .002), but the proportion of
patients with serious adverse events did not differ signiﬁ-
cantly between groups (7.8% vs 3.5%; P ¼ .15). CONCLU-
SIONS: In patients who underwent curative treatment for
HCC, adjuvant immunotherapy with activated CIK cells
increased recurrence-free and overall survival. ClinicalTrials.
gov number: NCT00699816.*Authors share co-ﬁrst authorship.
Abbreviations used in this paper: AE, adverse event; CI, conﬁdence in-
terval; CIK, cytokine-induced killer; HBV, hepatitis B virus; HCC, hepato-
cellular carcinoma; HR, hazard ratio; IL2, interleukin 2; MHC, major
histocompatibility complex; NK, natural killer; OS, overall survival; PEI,
percutaneous ethanol injection; RFA, radiofrequency ablation; RFS,
recurrence-free survival.Keywords: Liver Cancer; Clinical Trial; IL2; NK Cell.
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Tearly detection of hepatocellular carcinoma (HCC) in
high-risk populations has increased the likelihood of cura-
tive treatment.1,2 However, the long-term prognosis still ispoor even after a curative treatment because of the high
frequency of recurrence in the remnant liver.3 This high
recurrence rate has led efforts to develop adjuvant therapies
to reduce recurrence. However, the beneﬁt of any form of
adjuvant therapy remains unclear,4,5 and current scientiﬁc
guidelines do not recommend adjuvant therapy after cura-
tive treatment.6–8
Regarding adjuvant adoptive immunotherapy, cytokine-
induced killer (CIK) cell–based immunotherapy has become
a promising novel strategy. CIK cells are a mixture of T
lymphocytes, which are ex vivo expanded with cytokines,
comprising CD3þ/CD56þ cells, CD3-/CD56þ natural killer
(NK) cells, and CD3þ/CD56- cytotoxic T cells. Among them,
CD3þ/CD56þ T cells, which are rare in uncultured pe-
ripheral blood, are the main effector cells.9 They have a
high proliferation rate, potent antitumor effects with the
dual-functional capability of both T cells and NK cells, and
little cytotoxicity to normal cells, but with substantial
speciﬁcity to tumor cells.10,11 Earlier preclinical and clinical
studies also showed a potent antitumor activity of CIK cells
against various tumors.12–14 A previous clinical trial from
Japan reported that CIK cell immunotherapy increased
recurrence-free survival (RFS) after surgical resection of
HCC.15 Similar results were reproduced in 2 other clinical
trials.16,17 Preceding preclinical studies showed that CIK
cells killed HCC cells in vitro,18 were localized in cancer
mass in vivo,19 and induced no major side effects after
repeated transfer.20 Encouraged by these promising results,
the manufacturing techniques were reﬁned and standard-
ized, and an individualized autologous CIK cell–based
immunotherapeutic agent (Immuncell-LC; Green Cross Cell
Corp, Seoul, Korea) was developed. This CIK cell agent is
1384 Lee et al Gastroenterology Vol. 148, No. 7
CLINICAL
LIVERmanufactured by extracorporeal culture of respective pa-
tients’ peripheral blood mononuclear cells with co-
stimulation using interleukin 2 (IL2) and anti-CD3
antibody.
In this study, we aimed to assess the efﬁcacy and safety
of the CIK cell agent as an adjuvant therapy for HCC.Materials and Methods
Patients
Patients who had undergone curative treatment (surgical
resection, radiofrequency ablation [RFA], or percutaneous
ethanol injection [PEI]) for HCC of pretreatment clinical stage I
or II according to the American Joint Committee on Cancer
staging system (6th edition) based on radiologic imaging
studies were eligible for this study (Supplementary Table 1).21
The diagnosis of HCC was made by pathologic examination or
radiologic imaging studies.22 Eligibility criteria also included
hepatic function of Child–Pugh class A, an Eastern Cooperative
Oncology Group performance status score of 0 or 1, and age
between 20 and 80 years. Exclusion criteria included patients
with immune deﬁciency or autoimmune diseases, previous or
current other malignancies, and severe allergic disorder.
Pregnant or breast-feeding women and women planning to get
pregnant also were excluded.
Trial Design and Treatment
All participants provided written informed consent before
enrollment. The study protocol was approved by the institu-
tional review board at each participating center. All methods
and procedures associated with this study were conducted in
accordance with the Good Clinical Practice guidelines and
accorded ethically with the principles of the Declaration of
Helsinki and local laws. All authors had access to the study data
and reviewed and approved the ﬁnal manuscript.
This phase 3 clinical study was a multicenter, randomized,
open-labeled trial. The study was conducted at 5 university-
afﬁliated hospitals in Korea. All eligible participants were
assigned randomly, in a 1:1 ratio, to receive adjuvant adoptive
immune therapy using a CIK cell agent (the immunotherapy
group) or no adjuvant treatment (the control group). Random
assignment was performed through a central telephone system
using computer-generated, permuted blocks with a block size
of 4 or 6 and stratiﬁed according to study center.
During the pretreatment period, peripheral blood (120 mL)
for manufacturing the individualized CIK cell agent was
collected from the respective patients who were randomized to
the immunotherapy group at least 4 weeks before starting
treatment. The CIK cell agent was prepared at a central
manufacturing facility. Mononuclear cells were separated and
cultured for 12–21 days with IL2 and immobilized monoclonal
antibody to CD3 at 37C according to a modiﬁed protocol of the
original method (Supplementary Figure 1).10,23 Patients in the
immunotherapy group received 200 mL of the CIK cell agent
intravenously over 60 minutes without any premedication and
then were observed for at least 30 minutes. They were
scheduled to receive the CIK cell agent 16 times (4 treatments
at a frequency of once per week, followed by 4 treatments
every 2 weeks, then 4 treatments every 4 weeks, and ﬁnally 4
treatments every 8 weeks). Treatment could be delayed for amaximum of 2 weeks if the CIK cell agent was not manufac-
tured appropriately (Supplementary Table 2). Cytokines such
as interferon, chemotherapy agents, other immunotherapy
agents, hormonal therapy, and stem cell therapy were contra-
indicated during the study.End Points and Assessments
The primary end point was RFS. RFS was measured from
the date of randomization to the ﬁrst recurrence or to death
from any cause. The secondary end points included overall and
cancer-speciﬁc survivals and safety. Overall survival (OS) was
measured from the date of randomization until death from any
cause, and cancer-speciﬁc survival was measured from the date
of randomization until death resulting from HCC.
Tumor assessments were performed using dynamic
computed tomography or magnetic resonance imaging every 3
months from baseline for 24 months, and then every 3–6
months in both groups. All scans were reviewed by 2 inde-
pendent radiologists at each site with more than 5 years’
experience, who were unaware of the group assignment. In
cases of discordance, an additional third independent experi-
enced radiologist reviewed images and consensus was achieved
among the 3 radiologists. Adverse events (AEs), which were
classiﬁed and graded according to the Common Terminology
Criteria for Adverse Events, version 3.0, were assessed from the
time the patient provided written informed consent until the
end of the study or drop-out, and until at least 30 days after the
last dose of immunotherapy. Multiple occurrences of speciﬁc
events were counted once per patient; the event with the
greatest severity was summarized. The data cut-off date was
November 29, 2012.Statistical Analysis
Sample size for the study was determined on the basis of
the primary end point of RFS. Assuming a 1-sided type I error
of 0.05, a power of 80%, and a randomization ratio for 1:1
between the 2 study groups, 57 recurrences or death events
were required to expect a hazard ratio [HR] of 0.5, which was
estimated from a 22% point increase (from 45% to 67%) in the
2-year RFS rate.15 When the potential loss to follow-up rate was
set at 20%, 160 patients were needed to record 57 recurrence
events.
The interim analysis, which originally was planned for
sample size re-estimation, was performed by an independent
statistician using a cut-off date of November 30, 2009, by which
time the prespeciﬁed 28 recurrence or death events (approxi-
mately 50% of projected events) had occurred. By using an
interim hazard ratio, the adjusted hazard ratio was 0.58, indi-
cating the need to increase the event threshold to 86. The loss to
follow-up rate was adjusted to 4%. On the basis of these calcu-
lations, we re-estimated that we needed to enroll 230 patients.
The efﬁcacy outcomes were assessed according to the
intention-to-treat principle. Kaplan–Meier curves were
generated for RFS, OS, and cancer-speciﬁc survival and the log-
rank test was used for group comparisons. Unadjusted HRs
were estimated using the Cox proportional hazards model. To
compare the consistency of the effect of study treatment on
the primary end point with immunotherapy and with no
immunotherapy, we performed prespeciﬁed subgroup ana-
lyses as well as post hoc ones. A Cox proportional hazard
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Ranalysis was performed to assess the effect of baseline char-
acteristics on each outcome of interest. AEs were compared
between the 2 study groups using the chi-square test or the
Fisher exact test. The log-rank test for the primary end point
was 1-sided and all other statistical tests were 2-sided. Sta-
tistical signiﬁcance was set at a P value of less than .05. The
statistical analysis was performed by statisticians at the
Department of Statistics of Korea University (Seoul, Korea)
using SAS software version 9.2 (SAS Institute, Inc, Cary, NC);
the R statistical programming environment, version 2.15.3
(http://www.r-project.org); and STATA software version 13.0
(StataCorp, College Station, TX).
Results
Patients
Between July 3, 2008, and November 29, 2012, there
were 245 participants who were screened. A total of 230
eligible participants were assigned randomly to either the
immunotherapy group (n ¼ 115) or the control group (n ¼
115). Among these randomized patients, 226 (114 in the
immunotherapy group and 112 in the control group) were
included in the efﬁcacy analysis: 4 patients were excluded
from the efﬁcacy analysis because 1 in the immunotherapy
group and 3 in the control group were found to have violated
the inclusion and exclusion criteria according to a decision
from the steering committee. One patient in the immuno-
therapy group was lost to follow-up evaluation and 10 pa-
tients in the immunotherapy group discontinued
intervention. Also, 15 patients in the control group were lost
to follow-up (Supplementary Appendix). All 230 randomized
patients were included in the safety population. At the time
of the data cut-off date, the median follow-up duration was
40.0 months in the immunotherapy group and 36.5 months
in the control group.
None of the differences in the baseline characteristics
between the 2 study groups were statistically signiﬁcant,
except for platelet count (Table 1). Approximately 30% of
patients underwent surgical resection. Chronic hepatitis B
virus (HBV) infection was the predominant cause of liver
disease and approximately two thirds of patients had liver
cirrhosis. Time interval and modality of imaging studies
were comparable between study groups (Supplementary
Table 3). Patients in the immunotherapy group received
the CIK cell agent containing an average of 6.4 109 cells
per a treatment (Table 2).
Efﬁcacy
Recurrence-free survival. The median RFS was 14.0
months longer in the immunotherapy group (44.0 mo) than
in the control group (30.0 mo). The difference in RFS be-
tween the 2 groups was statistically signiﬁcant (P ¼ .010
by 1-sided log-rank test). Among the 226 patients in the
efﬁcacy population, a total of 101 patients experienced
tumor recurrence or death by the time of the data cut-off
date: 46 of the 114 patients (40%) in the immunotherapy
group (45 recurrences and 1 death without recurrence)
and 55 of the 112 patients (49%) in the control group
(53 recurrences and 2 deaths without recurrence). TheHR for tumor recurrence or death in the immunotherapy
group vs the control group was 0.63 (95% conﬁdence in-
terval [CI], 0.43–0.94), representing a 37% relative risk
reduction in the immunotherapy group (Figure 1A and
Supplementary Table 4). The immunotherapy consistently
reduced the risk of all 3 types of tumor recurrence: intra-
hepatic local recurrence (within 2 cm from resection or
ablation margin), intrahepatic distant recurrence (beyond
2 cm from margin), and extrahepatic recurrence
(Supplementary Figure 2).
On multivariate analysis using a stepwise selection
method, adjuvant immunotherapy was proven to be a sig-
niﬁcant prognostic factor (adjusted HR, 0.66; 95% CI,
0.44–0.98; P ¼ .04) after adjustment for age, serum level of
a-fetoprotein, and treatment modality (Supplementary
Table 5). Subgroup analyses according to prespeciﬁed and
post hoc factors showed a beneﬁt on RFS for adjuvant CIK
immunotherapy over the control group in most of the sub-
groups analyzed (Figure 2).
Among 100 patients (45 in the immunotherapy group
and 55 in the control group) who experienced tumor
recurrence, patients underwent additional treatment for a
median of 2 times (range, 0–17), with multidisciplinary
modalities including surgical resection, RFA, PEI,
transarterial chemoembolization, liver transplantation,
external radiation therapy, proton therapy, sorafenib, and
conventional cytotoxic chemotherapy (Supplementary
Table 6).
Overall and cancer-speciﬁc survival. At the time of
the data cut-off date, 15 deaths had occurred in the efﬁcacy
population: 3 patients in the immunotherapy group and 12
in the control group. In the immunotherapy group, patients
died of recurrent HCC (2 patients) or new primary gastric
cancer (1 patient). In the control group, patients died of
recurrent HCC (9 patients) or unknown causes (3 patients).
Both the median overall and cancer-speciﬁc survivals in
both groups were not reached. OS was longer in the
immunotherapy group than in the control group (HR, 0.21;
95% CI, 0.06–0.75; P ¼ .008) (Figure 1B). Recurrence status
signiﬁcantly affected OS (relative risk of death, 5.22; 95% CI,
1.52–18.01; P ¼ .003 by z-test). In addition, cancer-speciﬁc
survival was longer in the immunotherapy group (HR, 0.19;
95% CI, 0.04–0.87; P ¼ .02) (Figure 1C and Supplementary
Table 4).
Safety
AEs were reported for 118 patients (51%) in the safety
population and were mild to moderate (grade 1 or 2) for
109 patients (47%). Overall, AEs occurred more frequently
in the immunotherapy group (62%) than in the control
group (41%) (P ¼ .002), but the frequency of grade 3 or 4
AEs was comparable between 2 study groups (P ¼ .18).
Chills, pyrexia, and productive cough were reported more
frequently in the immunotherapy group (Table 3). The fre-
quency of serious AEs between 2 groups were comparable
(7.8% in the immunotherapy group vs 3.5% in the control
group; P ¼ .15).
The CIK cell agent–related adverse drug reactions
including pyrexia, chills, myalgia, and fatigue were reported
Table 1.Baseline Demographics and Disease Characteristics
Variable
Immunotherapy
(n ¼ 114)
Control group
(n ¼ 112) P value
Sex, N (%) NSa
Male 95 (83.3) 91 (81.3)
Female 19 (16.7) 21 (18.8)
Age, mean (SE), y 55.4 (8.2) 56.4 (10.6) NSb
Treatment modality,
N (%)
NSc
PEI 13 (11.4) 4 (3.6)
RFA 69 (60.5) 70 (62.5)
Surgical resection 32 (28.1) 38d (33.9)
HCC stage, N (%)e NSa
Stage I 98 (86.0) 94 (83.9)
Stage II 16 (14.0) 18 (16.1)
Number of HCC, N (%) NSc
3 2 (1.8) 2 (1.8)
<3 112 (98.2) 110 (98.2)
Size of HCC, cm .02f
Median 1.8 2.3
IQR (Q3–Q1) 1.4–2.3 1.5–3.1
ECOG performance
status, N (%)g
NSa
0 81 (71.1) 81 (72.3)
1 33 (28.9) 31 (27.7)
Cause of liver disease,
N (%)
NSc
HBV infection only 96 (84.2) 90 (80.4)
HCV infection only 9 (7.9) 10 (8.9)
HBV and HCV
co-infection
2 (1.8) 2 (1.8)
Others 7 (6.1) 10 (8.9)
Cirrhosis, N (%)h 76 (66.7) 70 (62.5) NSa
Biochemical analysis
a-fetoprotein level,
ng/mL
NSf
Median 5.2 5.4
IQR (Q1–Q3) 3.1–9.9 3.0–13.0
PIVKA-II, mAU/mL NSf
Median 19.0 18.0
IQR (Q3–Q1) 14.0–24.8 14.0–24.0
Aspartate
aminotransferase
level, IU/L
NSf
Median 33.0 34.0
IQR (Q1–Q3) 27.0–43.5 26.8–44.0
Alanine
aminotransferase
level, IU/L
NSf
Median 33.0 33.0
IQR (Q1–Q3) 25.0–45.8 23.0–47.5
Alkaline phosphatase
level, IU/L
NSf
Median 82.5 82.0
IQR (Q1–Q3) 70.0–101.5 65.0–100.0
Albumin level, g/dL NSf
Median 4.1 4.1
IQR (Q1–Q3) 3.9–4.3 3.9–4.3
Total bilirubin level,
mg/dL
NSf
Median 0.8 0.8
IQR (Q1–Q3) 0.6–1.0 0.6–1.0
Table 1.Continued
Variable
Immunotherapy
(n ¼ 114)
Control group
(n ¼ 112) P value
Prothrombin time, s NSf
Median 13.7 13.9
IQR (Q1–Q3) 13.1–14.7 13.2–14.4
Creatinine level,
mg/dL
NSf
Median 0.9 0.9
IQR (Q1–Q3) 0.8–1.0 0.7–1.0
Platelet, 103/mm3 .01f
Median 116.5 141.0
IQR (Q1–Q3) 92.3–158.0 117.5–166.3
NOTE. Data are expressed as n (%), mean (SE), or median
with interquartile range.
ECOG, Eastern Cooperative Oncology Group; HCV, hepatitis
C virus; IQR, interquartile range; PIVKA-II, protein induced by
vitamin K absence-II.
aChi-square test.
bBy 2-sample t test.
cFisher exact test.
dTwo of them underwent intraoperative RFA in addition to
surgical resection.
eThe HCC staging was performed according to the American
Joint Committee on Cancer staging system (6th ed).21
fWilcoxon rank-sum test.
gThe ECOG performance status assesses the daily living
abilities of the patient, on a scale ranging from 0 (fully active)
to 5 (dead).
hCirrhosis was diagnosed by the presence of histologic and
radiologic evidence.
1386 Lee et al Gastroenterology Vol. 148, No. 7
CLINICAL
LIVERin 19 patients (17%), however, they did not delay or stop
the treatment. One patient in the immunotherapy group
dropped out because of serious AEs (new primary gastric
cancer), which, however, was not assessed as an adverse
drug reaction.Discussion
In this trial, patients who received an adjuvant immu-
notherapy using the CIK cell agent after curative treatment
for HCC had a 14-month median RFS beneﬁt, as compared
with those who received no adjuvant immunotherapy. At
the ﬁnal analysis, patients in the immunotherapy group had
a median RFS of 44.0 months, as compared with 30.0
months in the control group. The effect of the CIK cell agent
on RFS remained signiﬁcant after adjustment for baseline
prognostic factors of recurrence.
This trial showed that adjuvant immunotherapy
improved overall and cancer-speciﬁc survival in HCC pa-
tients. The magnitude of absolute survival gain in the
immunotherapy group was modest, but the relative risk
reduction was signiﬁcant (approximately four-ﬁfths rela-
tive risk reduction of both overall and cancer-speciﬁc
mortalities in the immunotherapy group). In contrast,
previous studies using uncommercialized CIK cells showed
Figure 1. Kaplan–Meier estimates of RFS, OS, and cancer-
speciﬁc survival. (A) RFS was computed for all patients
included in the efﬁcacy population. Patients who had not
progressed or died were censored on the data cut-off date.
(B) OS was computed for all patients included in the efﬁcacy
population. Patients who had not died were censored on the
data cut-off date. (C) Cancer-speciﬁc survival was computed
for all patients included in the efﬁcacy population. Patients
who had not died of hepatocellular carcinoma were censored
on the date of death owing to other causes or the data cut-off
date.
Table 2.Summary of Injected CIK Cell Agents: Safety
Population
Immunotherapy (n ¼ 115)
Total cell count, 109
Mean ± SD 6.4 ± 2.1
Range 1.4–20.0
Cell viability, %
Mean ± SD 97.4 ± 2.2
Range 90–100
CD3þ cell, %
Mean ± SD 98.3 ± 2.5
Range 80.3–100
CD8þ cell, %
Mean ± SD 83.8 ± 7.9
Range 60.1–98.4
CD56þ cell, %
Mean ± SD 27.1 ± 9.9
Range 10–76.9
CD14þ cell, %
Mean ± SD 0.1 ± 0.1
Range 0.0–0.7
CD20þ cell, %
Mean ± SD 0.1 ± 0.1
Range 0.0–0.9
Injection times
0 5 (4.4%)a
1–3 4 (3.5%)
4–7 2 (1.7%)
8–11 14 (12.2%)
12–15 7 (6.1%)
16 83 (72.2%)
Total 1569
NOTE. Data are expressed as mean ± SD, range, or n (%).
aThree patients withdrew informed consent, 1 patient failed
blood collection, and 1 patient had a protocol violation.
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Rsigniﬁcant beneﬁts in preventing recurrence, but no sig-
niﬁcant survival gains.15–17 The intensiﬁed schedule of CIK
cell agent administration and favorable tumor characteris-
tics in our study may account for the improved OS in
contrast to previous trials. CIK cells were infused more
times (16 times) in our study than in preceding studies
(3–10 times). In our study, only patients with American
Joint Committee on Cancer clinical stage I or II HCC were
included, whereas preceding studies included patients with
more advanced stage tumor (ie, high proportion of stage III
or IV tumors, 46%15; tumors with vascular invasion,
46%17; or large HCCs of > 5 cm, >60%16). Patients with
greater tumor burden in those preceding studies might
have had increased numbers of immune-suppressor cells
that can attenuate the effect of adjuvant immuno-
therapy,24,25 and thus might have impeded the survival
beneﬁt. In addition, our study used commercialized CIK cell
agents manufactured in a Good Manufacturing Practice-
certiﬁed central facility following standard operating pro-
cedures under strict quality control and assurance, whereas
the CIK cell preparation was performed by their own
cultivating methods in the previous studies.
HCC development and progression is well known to be
related to chronic inﬂammation.26 After tumor cells are
Figure 2. Recurrence-free survival in selected subsets. The graph show the estimates of the HR for every subgroup as a
square (whose size is proportional to the amount of information) and the horizontal lines depict the 95% CIs, which were
calculated by means of a Cox proportional hazards model. The diamond indicates the HRs with 95% CIs for all patients
enrolled. The vertical solid line at the HR of unity corresponds to the line of no effect. HR values of less than unity correspond to
a reduction in the risk of recurrence or death with immunotherapy. Patients co-infected with both HBV and HCV were included
in the HCV subset. HBV DNA and antiviral agent groups 1, 2, 3, and 4 indicate patients with serum HBV-DNA levels  2000
IU/mL who underwent antiviral treatment; those with serum HBV-DNA levels  2000 IU/mL who underwent no antiviral
treatment; those with HBV-DNA levels < 2000 IU/mL who underwent antiviral treatment; and those with HBV-DNA levels
< 2000 IU/mL who underwent no antiviral treatment, respectively. *Characteristics were post hoc subgroups. AFP,
a-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, Eastern
Cooperative Oncology Group; HCV, hepatitis C virus.
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and the immune cells present during chronic inﬂammation
may create conditions more favorable for tumor cell
survival.27 Immune-suppressor cells (eg, tumor-associated
macrophages, regulatory T cells, or myeloid-derived sup-
pressive cells) facilitate tumor immune evasion.28 Effector
cells (eg, dendritic cells, cytotoxic T cells, and NK cells)
decrease and their effectiveness is impaired in the tumor
microenvironment.29 In addition, because growing tumors
acquire mutations to evade the immune system30 and
antigen-presenting cells and CD8þ T cells are functionally
impaired, major histocompatibility complex (MHC)-
restricted cytotoxic immunity is incapacitated.31 Toovercome the aforementioned limitations of the cytotoxic
immune response against HCC, potentially effective strate-
gies should include enhancing MHC-unrestricted direct
cytotoxic effector cells; thus, we selected CD3þ/CD56þ CIK
cells as a potential answer. Within a certain period of
in vitro incubation with IL2 and anti-CD3 antibody, the
precursors (CD3þ T cells) can acquire an MHC-unrestricted,
cell-mediated cytotoxicity in addition to T-cell recep-
tor–mediated cytotoxicity after gaining CD56.32–34 Approx-
imately 27% of infused lymphocytes had CD56 in our study.
Compared with CD3þ/CD56- T cells, CD3þ/CD56þ CIK cells
have a higher proportion of CD8þ cells and a higher gran-
zyme content.35 Consequently, CD3þ/CD56þ CIK cells exert
Table 3.Adverse Events: Safety Population
Adverse event
Immunotherapy (n ¼ 115) Control (n ¼ 115)
P valueAll AE Related AE All AE
Any grade Grade 3 or 4
Any
grade Grade 3 or 4
Any
grade Grade 3 or 4
Any
grade Grade 3 or 4
Overall incidence 71 (62%) 7 (6%) 40 (35%) 0 47 (41%) 4 (4%) .002a .354a
Vomiting 3 (3%) 0 1 (1%) 0 3 (3%) 1 (1%) 1.00b 1.00b
Chills 10 (9%) 0 9 (8%) 0 0 0 .001a NAb
Fatigue 11 (10%) 0 3 (3%) 0 3 (3%) 0 .03a NAb
Pyrexia 13 (11%) 0 10 (9%) 0 0 0 <.001a NAb
URI 7 (6%) 0 0 0 3 (3%) 0 .20a NAb
Headache 3 (3%) 0 2 (2%) 0 1 (1%) 1 (1%) .62b 1.00b
Productive cough 6 (5%) 0 0 0 0 0 .03b NAb
NOTE. Listed are adverse events, as deﬁned by the National Cancer Institute Common Terminology Criteria (version 3.0), that
were considered drug-related or that occurred in at least 3 patients in either study group regardless of relationship to drug.
Data are expressed as N (%).
AE, adverse event; URI, upper respiratory tract infection.
aChi-square test.
bFisher exact test.
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Rmore potent antitumor toxicity than CD3þ/CD56- T cells in
in vitro studies.35,36 CD3þ/CD56þ CIK cells kill tumor cells
with granzyme and perforin-mediated tumor cell lysis after
tumor recognition.37–39
As shown in Figure 1A, our study as well as the previous
3 trials consistently showed that CIK cell treatment im-
proves RFS by reducing the risk of early recurrence (within
the ﬁrst 2 years), but fails to affect late recurrence (beyond
2 years).15–17 Because early recurrence of HCC is related
closely to metastasis of remnant neoplastic cells rather than
de novo hepatocarcinogenesis,40 clearing residual HCC cells
using CIK cells might explain the reduced early recurrence,
which consequently improved RFS. The CIK cell immuno-
therapy reduced all types of tumor recurrence: local intra-
hepatic recurrence, distant intrahepatic recurrence, and
extrahepatic recurrence. In addition to the direct tumor-
killing effect of the CIK cell agent, there also could be an
indirect mechanism of reducing tumor recurrence by con-
trolling the replication of HBV, which was the predominant
cause of HCC in this study. It has been reported that
autologous CIK cells could suppress HBV replication,41
which could reduce the risk of HCC recurrence in HBV-
related HCC patients.42,43 However, the effect of CIK cells
on the hepatitis C virus has not been evaluated fully and
further studies are required.
Further studies comparing the pretreatment factors and
post-treatment immunologic responses generated by the
CIK cell agent between the responders and the non-
responders also are warranted because the results might
enable the stratiﬁcation of patients who might derive more
beneﬁt from CIK cell immunotherapy, and also might
enhance the efﬁcacy of CIK cell therapy. Recent studies have
suggested several potential biomarkers including the post-
treatment CD4/CD8 ratio, the percentages of T cells and
NK cells, and B7 family molecules.44–46Although this trial was a randomized trial, there were
several baseline characteristics that were imbalanced be-
tween study groups: tumor size, platelet count, and prior
curative treatment modality. The immunotherapy group
had signiﬁcantly smaller tumors, which might favor the
immunotherapy group. In contrast, a signiﬁcantly lower
platelet count and a marginally higher proportion of abla-
tive therapy (RFA and PEI) in the immunotherapy group
might have had a negative impact on the effectiveness of
immunotherapy.47,48 In preplanned multivariate analysis
and subgroup analysis, those imbalanced baseline charac-
teristics were proven to have no signiﬁcant impact on the
effectiveness of CIK cell immunotherapy. In our study, pa-
tients were stratiﬁed solely by treatment center. In a future
study of adjuvant therapy, to avoid both overstratiﬁcation
and imbalance among important prognostic factors, it
would be better to stratify patients according to several key
prognostic factors such as tumor size and treatment
modality.49
The overall differences in serum aminotransferase levels
between the 2 study groups were not signiﬁcantly different
(Supplementary Table 7), which indicates that repeated
transfer of CIK cells did not cause signiﬁcant hepatocellular
injury. Although overall AEs were more frequent in the
immunotherapy group, they were mainly grades 1 or 2 in
severity and the frequency of serious AEs was comparable
between both groups. Most adverse drug reactions were not
linked to stopping or delaying adjuvant treatment. These
results collectively suggested that treatment with the CIK
cell agent was safe and well tolerated.
In conclusion, this study showed that adjuvant CIK cell
immunotherapy prolongs RFS and OS in patients who have
undergone curative treatment for HCC. The immunotherapy
was associated with a higher frequency of AEs, which were
mainly mild to moderate.
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Supplementary Appendix. CONSORT diagram. Of the
enrolled patients, 15 did not meet inclusion criteria and thus
were excluded from random assignment. In addition, 4 more
patients were excluded from the efﬁcacy analysis because
they were found to violate inclusion criteria after randomiza-
tion according to a decision from the steering committee.
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Supplementary Figure 1.Manufacturing process of CIK cell agent. After collection of peripheral blood from the respective
patients (day 0), mononuclear cells were separated and cultured for 12–21 days with interleukin 2 (from day 0 to the date of
harvest) and anti-CD3 monoclonal antibody (from day 0 to day 5). Tests for sterility and mycoplasma were performed twice at 3
days before harvest and at the date of harvest. Tests for identiﬁcation, purity, and potency were performed 1 day before
harvest. At the date of harvest, CIK cell agents were administered to patients. HCV, hepatitis C virus; HIV, human immuno-
deﬁciency virus; PBMC, peripheral blood mononuclear cell. aSterility test included aerobic and anaerobic bacteria and fungi.
bIdentiﬁcation included proportions of CD3þ, CD8þ, and CD56þ cells. cPurity test included proportions of CD14þ and CD20
CD3þcells.
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Supplementary Figure 2. Kaplan–Meier estimates of RFS
according to the respective recurrence site. (A) Intrahepatic
local recurrence (within 2 cm from surgical or ablation margin:
HR, 0.85; 95% CI, 0.44–1.62; P ¼ .30 by 1-sided log-rank
test), (B) intrahepatic distant recurrence (beyond 2 cm from
margin: HR, 0.63; 95% CI, 0.37–1.07; P ¼ .04 by 1-side log-
rank test), and (C) extrahepatic recurrence (HR, 0.17; 95% CI,
0.02–0.15; P ¼ .03 by 1-side log-rank test). RFS was
computed on all patients included in the efﬁcacy population.
Patients who had not progressed or died were censored on
data cut-off date.
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Supplementary Table 1.The Deﬁnition of Hepatocellular Carcinoma of Pretreatment Clinical Stage I or II According to the
American Joint Committee on Cancer Staging System Sixth Edition
Stage
I A solitary tumor without vascular invasion, lymph node metastasis, and distant metastasis
II A solitary tumor with vascular invasion, but without lymph node metastasis, and distant metastasis; or
multiple tumors, none more than 5 cm, without vascular invasion, lymph node metastasis, and distant metastasis
NOTE. Clinical stage was based primarily on the radiologic evaluation before treatment.
Supplementary Table 2.The Criteria of “Appropriate
Manufacture of Biologic Agents”
Following the Guidance from US
Food and Drug Administration,
Center for Biologics Evaluation and
Research
Sterility test No growth of aerobes, anaerobes, and fungi
Mycoplasma test Negative
Endotoxin test Negative
Viability and content Proportion of viable cells,  90%
Total cell counts, 1.0  109–2.0  1010 cells
NOTE. (http://www.fda.gov/BiologicsBloodVaccines/Guidance
ComplianceRegulatoryInformation/Guidances/Xenotransplan
tation/ucm074131.htm).
Supplementary Table 3.Summary of Imaging Studies
Immunotherapy (n ¼ 114) Control group (n ¼ 112) P value
Interval between each imaging study, days (per participants)
Before 96 weeks, median (range) 78 (41–90) 77 (41–84) .10a
After 96 weeks, median (range) 114 (74–182) 113 (63–168) .32a
Number of overall imaging studies, N (per participants) <.001b
Mean ± SD 9.0 ± 4.6 7.1 ± 4.8
Number of each imaging modalities, N (%) (overall participants) .68c
CT 1106 (98.2%) 887 (98.5%)
MRI 20 (1.8%) 13 (1.5%)
CT, computed tomography; MRI, magnetic resonance imaging.
aWilcoxon rank-sum test.
bTwo-sample t test.
cChi-square test.
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Supplementary Table 4.Summary of Efﬁcacy Measures: Efﬁcacy Population
Outcome Immunotherapy (n ¼ 114) Control (n ¼ 112) Hazard ratio (95% CI) P value
Recurrence-free survival rate
12 months 79.9% 65.1%
24 months 72.5% 53.8%
36 months 60.9% 44.3%
48 months 49.6% 39.6%
Recurrence-free survival, mo 0.63 (0.43–0.94) .010
Median 44.0 30.0
Overall survival rate
12 months 100.0% 98.0%
24 months 100.0% 91.8%
36 months 97.5% 88.1%
48 months 95.9% 84.8%
Overall survival, mo 0.21 (0.06–0.75) .008
Median NA NA
Cancer-speciﬁc survival rate
12 months 100.0% 98.0%
24 months 100.0% 94.9%
36 months 98.8% 91.0%
48 months 97.2% 87.5%
Cancer-speciﬁc survival, mo 0.19 (0.04–0.87) .020
Median NA NA
NOTE. Data are expressed as a percentage, hazard ratio with 95% CI, or median.
Supplementary Table 5.Univariate and Multivariate Analyses of Factors Associated With Recurrence-Free Survival
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age, 60 vs <60 y 1.58 (1.06–2.34) .02 1.52 (1.01–2.28) .04
Sex, male vs female 1.17 (0.68–2.03) .84
Etiology of liver disease, HBV or HCV vs NBNC 0.82 (0.40–1.69) .59
Cirrhosis, yes vs no 1.26 (0.82–1.92) .28
AFP level, 20 vs <20 ng/mL 1.74 (1.04–2.89) .03 2.12 (1.24–3.60) .006
ECOG performance status, 0 vs 1 1.40 (0.90-2.18) .71
Histologic conﬁrmation, yes vs no 0.85 (0.57–1.28) .43
HCC maximal diameter, 2 vs <2 cm 1.20 (0.81–1.78) .34
Treatment modality, RFA or PEI vs surgery 1.50 (0.94–2.37) .054 1.75 (1.08–2.83) .02
Platelet count, 140 vs <140  103/mm3 0.93 (0.62–1.38) .70
AST level, 40 vs <40 IU/L 1.43 (0.96–2.12) .07
ALT level, 40 vs <40 IU/L 1.01 (0.67–1.52) .96
ALP level, 115 vs <115 IU/L 1.11 (0.65–1.90) .69
PIVKA-II level, 40 vs <40 AU/mL 0.71 (0.26–1.95) .50
Albumin level, 3.5 vs <3.5 g/dL 1.18 (0.48–2.92) .71
Bilirubin level, 1.2 vs <1.2 mg/dL 1.11 (0.66–1.87) .69
Prothrombin time, 13 vs <13 s 1.01 (0.60–1.70) .98
Creatinine level, 1.2 vs <1.2 mg/dL 1.15 (0.53–2.48) .72
Treatment group, immunotherapy vs control group 0.63 (0.43–0.94) .01a 0.66 (0.44–0.98) .04
AFP, a-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG,
Eastern Cooperative Oncology Group; HCV, hepatitis C virus; NBNC, non-HBV and non–hepatitis C virus; PIVKA-II, protein
induced by vitamin K absence-II.
aBy a 1-sided test. Otherwise, a 2-sided test was used.
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Supplementary Table 6.Postrecurrence Treatment
Modalities in the Immunotherapy
Group and the Control Group
Treatment modalities
Immunotherapy
(n ¼ 45)
Control
(n ¼ 55)
Transarterial chemoembolization 98 126
Radiofrequency ablation 25 29
Percutaneous ethanol injection 21 17
Surgical resection 4 6
Liver transplantation 2 2
Sorafenib 3 4
Conventional chemotherapy 2 1
Radiation therapy 4 4
Proton therapy 0 1
Total 159 190
Supplementary Table 7.Changes in Serum Levels of a-Fetoprotein, Aspartate Aminotransferase, and Alanine
Aminotransferase: Efﬁcacy Population
Variable Immunotherapy (n ¼ 114) Control (n ¼ 112) P valuea
a-fetoprotein level, ng/mL
Baseline 11.3 (18.6) 9.2 (13.6)
End of study 14.5 (38.9) 53.1 (439.4)
Change from baseline 3.6 (40.4) 49.3 (463.3) .58
P valueb .12 .48
Aspartate aminotransferase level, IU/L
Baseline 41.9 (30.9) 39.0 (18.1)
End of study 38.0 (23.6) 37.5 (20.2)
Change from baseline -3.8 (32.2) -1.3 (18.9) .83
P valueb .07 .10
Alanine aminotransferase level, IU/L
Baseline 41.5 (36.4) 40.2 (22.1)
End of study 35.1 (23.6) 38.8 (29.8)
Change from baseline -6.4 (35.7) -0.6 (25.8) .52
P valueb .01 .12
NOTE. Data are expressed as mean (SD).
aWilcoxon rank-sum test comparing changes in the indicated parameters of 2 groups from baseline.
bWilcoxon signed-rank test comparing changes in the indicated parameters within each group from baseline.
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